These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 27034329

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
    Lai C, Coltart G, Shapanis A, Healy C, Alabdulkareem A, Selvendran S, Theaker J, Sommerlad M, Rose-Zerilli M, Al-Shamkhani A, Healy E.
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
    [Abstract] [Full Text] [Related]

  • 3. OX40 costimulation turns off Foxp3+ Tregs.
    Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Li XC.
    Blood; 2007 Oct 01; 110(7):2501-10. PubMed ID: 17575071
    [Abstract] [Full Text] [Related]

  • 4. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A, Schlößer H, Rothschild SI, Thelen M, Reuter S, Zentis P, Shimabukuro-Vornhagen A, Theurich S, Wennhold K, Garcia-Marquez M, Tharun L, Quaas A, Schauss A, Isensee J, Hucho T, Huebbers C, von Bergwelt-Baildon M, Beutner D.
    Oncotarget; 2017 Jul 04; 8(27):44418-44433. PubMed ID: 28574843
    [Abstract] [Full Text] [Related]

  • 5. OX40/OX40L costimulation affects induction of Foxp3+ regulatory T cells in part by expanding memory T cells in vivo.
    Xiao X, Kroemer A, Gao W, Ishii N, Demirci G, Li XC.
    J Immunol; 2008 Sep 01; 181(5):3193-201. PubMed ID: 18713990
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
    Chen X, Subleski JJ, Kopf H, Howard OM, Männel DN, Oppenheim JJ.
    J Immunol; 2008 May 15; 180(10):6467-71. PubMed ID: 18453563
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.
    Clin Cancer Res; 2017 Oct 15; 23(20):6165-6177. PubMed ID: 28855348
    [Abstract] [Full Text] [Related]

  • 13. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
    Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, Hashimoto K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May 15; 109(5):744-52. PubMed ID: 20303300
    [Abstract] [Full Text] [Related]

  • 14. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
    Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ.
    J Immunol; 2013 Oct 01; 191(7):3641-50. PubMed ID: 24014877
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.
    Imianowski CJ, Kuo P, Whiteside SK, von Linde T, Wesolowski AJ, Conti AG, Evans AC, Baird T, Morris BI, Fletcher NE, Yang J, Poon E, Lakins MA, Yamamoto M, Brewis N, Morrow M, Roychoudhuri R.
    Cancer Res Commun; 2024 Aug 01; 4(8):2045-2057. PubMed ID: 38995700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.